OTC Statin Target Population Receives Significant FDA Attention
This article was originally published in The Tan Sheet
Executive Summary
The type of people most suited for OTC statin therapy received considerable attention from FDA during the agency's discussion on the OTC availability of vascular drugs at a public meeting in Gaithersburg, Md. June 28-29.
You may also be interested in...
OTC Switch Expert Panels Supported By AHA
The American Heart Association supports establishing expert panels that would determine what additional research is needed before a decision on a potential switch candidate can be made. The association's comments refer specifically to statin drugs.
Pravachol OTC Marketing Retailer Involvement Anticipated By BMS
A Pravachol OTC marketing program designed to emphasize the "importance of keeping the doctor in the loop" would include point-of-purchase messages encouraging physician consultation, Bristol-Myers Squibb Rx-to-OTC Marketing Senior Director Patricia Kriger told FDA advisory committees July 14.
Benecol, Statins Combined Use Outperforms Increased Statin Doses - Study
Concomitant use of McNeil Consumer Healthcare's Benecol spread with Rx statin drugs more effectively reduces total cholesterol and low-density lipoprotein (LDL) cholesterol levels than a doubled dose of the original statin, a recently published study reports.